Aprepitant inhibits the progression of esophageal squamous cancer by blocking the truncated neurokinin‑1 receptor

Zheng,Yang; Sang,Meixiang; Liu,Fei; Gu,Lina; Li,Juan; Wu,Yunyan; Shan,Baoen

doi:10.3892/or.2023.8568

Aprepitant inhibits the progression of esophageal squamous cancer by blocking the truncated neurokinin‑1 receptor

Authors:
- Yang Zheng
- Meixiang Sang
- Fei Liu
- Lina Gu
- Juan Li
- Yunyan Wu
- Baoen Shan
View Affiliations

Affiliations: Research Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050017, P.R. China
Published online on: May 9, 2023 https://doi.org/10.3892/or.2023.8568
Article Number: 131
Copyright: © Zheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Increasing evidence showed that the substance P (SP)/neurokinin‑1 receptor (NK1R) complex is involved in the development of several cancers. However, little is known about the mechanisms by which SP/NK1R complex plays a role in esophageal squamous cell carcinoma (ESCC) progression. RT‑qPCR, CCK‑8, Transwell, western blotting, immunohistochemical, immunofluorescence, ELISA and analysis of apoptosis were employed in the present study. It was aimed to investigate the function and therapeutic potential of the SP/tr‑NK1R system in human ESCC progression. The results revealed that both SP and tr‑NK1R were highly expressed in ESCC cell lines and specimens. In ESCC tissues, SP was mainly derived from ESCC cells and M2 macrophages. The NK1R antagonist aprepitant inhibited the SP‑induced proliferation of human ESCC cell lines. Aprepitant inhibited cell migration and invasion and induced apoptosis of ESCC cells by downregulating the PI3K/AKT/mTOR signaling pathways. Animal experiments revealed that aprepitant inhibited tumor progression of ESCC in xenograft mice. In conclusion, high expression of SP plus tr‑NK1R indicated poor prognosis in ESCC, suggesting that aprepitant has a potential application in ESCC. To the best of our knowledge, high SP and tr‑NK1R expression in ESCC cell lines was reported for the first time in the present study. These findings provided evidence for a novel therapeutic strategy for patients with ESCC.

View Figures

View References

1	Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022. View Article : Google Scholar : PubMed/NCBI
2	Abnet CC, Arnold M and Wei WQ: Epidemiology of esophageal squamous cell carcinoma. Gastroenterology. 154:360–373. 2018. View Article : Google Scholar : PubMed/NCBI
3	Coveñas R and Muñoz M: Cancer progression and substance P. Histol Histopathol. 29:881–890. 2014.PubMed/NCBI
4	González-Moles MÁ, Ramos-García P and Esteban F: Significance of the overexpression of substance P and its receptor NK-1R in head and neck carcinogenesis: A systematic review and meta-analysis. Cancers (Basel). 13:13492021. View Article : Google Scholar : PubMed/NCBI
5	Patel HJ, Ramkissoon SH, Patel PS and Rameshwar P: Transformation of breast cells by truncated neurokinin-1 receptor is secondary to activation by preprotachykinin-A peptides. Proc Natl Acad Sci USA. 102:17436–17441. 2005. View Article : Google Scholar : PubMed/NCBI
6	Gillespie E, Leeman SE, Watts LA, Coukos JA, O'Brien MJ, Cerda SR, Farraye FA, Stucchi AF and Becker JM: Truncated neurokinin-1 receptor is increased in colonic epithelial cells from patients with colitis-associated cancer. Proc Natl Acad Sci USA. 108:17420–17425. 2011. View Article : Google Scholar : PubMed/NCBI
7	Ramkissoon SH, Patel PS, Taborga M and Rameshwar P: Nuclear factor-kappaB is central to the expression of truncated neurokinin-1 receptor in breast cancer: Implication for breast cancer cell quiescence within bone marrow stroma. Cancer Res. 67:1653–1659. 2007. View Article : Google Scholar : PubMed/NCBI
8	Berger M, Neth O, Ilmer M, Garnier A, Salinas-Martín MV, de Agustín Asencio JC, von Schweinitz D, Kappler R and Muñoz M: Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo. J Hepatol. 60:985–994. 2014. View Article : Google Scholar : PubMed/NCBI
9	Deng XT, Tang SM, Wu PY, Li QP, Ge XX, Xu BM, Wang HS and Miao L: SP/NK-1R promotes gallbladder cancer cell proliferation and migration. J Cell Mol Med. 23:7961–7973. 2019. View Article : Google Scholar : PubMed/NCBI
10	Inoue T, Kimura M, Uchida J, Nishino K, Kumagai T, Taniguchi J and Imamura F: Aprepitant for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Int J Clin Oncol. 22:600–604. 2017. View Article : Google Scholar : PubMed/NCBI
11	Yahata H, Kobayashi H, Sonoda K, Shimokawa M, Ohgami T, Saito T, Ogawa S, Sakai K, Ichinoe A, Ueoka Y, et al: Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: A multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin. Int J Clin Oncol. 21:491–497. 2016. View Article : Google Scholar : PubMed/NCBI
12	Muñoz M and Coveñas R: Neurokinin-1 receptor antagonists as antitumor drugs in gastrointestinal cancer: A new approach. Saudi J Gastroenterol. 22:260–268. 2016. View Article : Google Scholar : PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	Douglas SD and Leeman SE: Neurokinin-1 receptor: Functional significance in the immune system in reference to selected infections and inflammation. Ann N Y Acad Sci. 1217:83–95. 2011. View Article : Google Scholar : PubMed/NCBI
15	Ge C, Huang H, Huang F, Yang T, Zhang T, Wu H, Zhou H, Chen Q, Shi Y, Sun Y, et al: Neurokinin-1 receptor is an effective target for treating leukemia by inducing oxidative stress through mitochondrial calcium overload. Proc Natl Acad Sci USA. 116:19635–19645. 2019. View Article : Google Scholar : PubMed/NCBI
16	Chanmee T, Ontong P, Konno K and Itano N: Tumor-associated macrophages as major players in the tumor microenvironment. Cancers (Basel). 6:1670–1690. 2014. View Article : Google Scholar : PubMed/NCBI
17	Zhou Y, Zhao L, Xiong T, Chen X, Zhang Y, Yu M, Yang J and Yao Z: Roles of full-length and truncated neurokinin-1 receptors on tumor progression and distant metastasis in human breast cancer. Breast Cancer Res Treat. 140:49–61. 2013. View Article : Google Scholar : PubMed/NCBI
18	Lewis KM, Harford-Wright E, Vink R and Ghabriel MN: NK1 receptor antagonists and dexamethasone as anticancer agents in vitro and in a model of brain tumours secondary to breast cancer. Anticancer Drugs. 24:344–354. 2013. View Article : Google Scholar : PubMed/NCBI
19	Javid H, Mohammadi F, Zahiri E and Hashemy SI: The emerging role of substance P/neurokinin-1 receptor signaling pathways in growth and development of tumor cells. J Physiol Biochem. 75:415–421. 2019. View Article : Google Scholar : PubMed/NCBI
20	Garcia-Recio S, Fuster G, Fernandez-Nogueira P, Pastor-Arroyo EM, Park SY, Mayordomo C, Ametller E, Mancino M, Gonzalez-Farre X, Russnes HG, et al: Substance P autocrine signaling contributes to persistent HER2 activation that drives malignant progression and drug resistance in breast cancer. Cancer Res. 73:6424–6434. 2013. View Article : Google Scholar : PubMed/NCBI
21	Ma J, Yuan S, Cheng J, Kang S, Zhao W and Zhang J: Substance P promotes the progression of endometrial adenocarcinoma. Int J Gynecol Cancer. 26:845–850. 2016. View Article : Google Scholar : PubMed/NCBI
22	Esteban F, Muñoz M, González-Moles MA and Rosso M: A role for substance P in cancer promotion and progression: A mechanism to counteract intracellular death signals following oncogene activation or DNA damage. Cancer Metastasis Rev. 25:137–145. 2006. View Article : Google Scholar : PubMed/NCBI
23	Mohammadi F, Javid H, Afshari AR, Mashkani B and Hashemy SI: Substance P accelerates the progression of human esophageal squamous cell carcinoma via MMP-2, MMP-9, VEGF-A, and VEGFR1 overexpression. Mol Biol Rep. 47:4263–4272. 2020. View Article : Google Scholar : PubMed/NCBI
24	Mayordomo C, García-Recio S, Ametller E, Fernández-Nogueira P, Pastor-Arroyo EM, Vinyals L, Casas I, Gascón P and Almendro V: Targeting of substance P induces cancer cell death and decreases the steady state of EGFR and Her2. J Cell Physiol. 227:1358–1366. 2012. View Article : Google Scholar : PubMed/NCBI
25	Cui Y, Zhang S, Hu X and Gao F: Tumor-associated fibroblasts derived exosomes induce the proliferation and cisplatin resistance in esophageal squamous cell carcinoma cells through RIG-I/IFN-β signaling. Bioengineered. 13:12462–12474. 2022. View Article : Google Scholar : PubMed/NCBI
26	Ho WZ, Lai JP, Zhu XH, Uvaydova M and Douglas SD: Human monocytes and macrophages express substance P and neurokinin-1 receptor. J Immunol. 159:5654–5660. 1997. View Article : Google Scholar : PubMed/NCBI
27	Dupuis LL, Lingertat-Walsh K and Walker SE: Stability of an extemporaneous oral liquid aprepitant formulation. Support Care Cancer. 17:701–706. 2009. View Article : Google Scholar : PubMed/NCBI
28	Munoz M, Covenas R, Esteban F and Redondo M: The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs. J Biosci. 40:441–463. 2015. View Article : Google Scholar : PubMed/NCBI
29	Rapoport BL, Jordan K, Boice JA, Taylor A, Brown C, Hardwick JS, Carides A, Webb T and Schmoll HJ: Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: A randomized, double-blind study. Support Care Cancer. 18:423–431. 2010. View Article : Google Scholar : PubMed/NCBI
30	Muñoz M and Rosso M: The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug. Invest New Drugs. 28:187–193. 2010. View Article : Google Scholar : PubMed/NCBI
31	Palma C, Bigioni M, Irrissuto C, Nardelli F, Maggi CA and Manzini S: Anti-tumour activity of tachykinin NK1 receptor antagonists on human glioma U373 MG xenograft. Br J Cancer. 82:480–487. 2000. View Article : Google Scholar : PubMed/NCBI
32	Bigioni M, Benzo A, Irrissuto C, Maggi CA and Goso C: Role of NK-1 and NK-2 tachykinin receptor antagonism on the growth of human breast carcinoma cell line MDA-MB-231. Anticancer Drugs. 16:1083–1089. 2005. View Article : Google Scholar : PubMed/NCBI